pSiMedica is now a fully owned subsidiary of pSivida Limited. pSivida is committed to the development of drug delivery products in the healthcare sector, initially in Ophthalmology and Oncology. pSivida has developed the only two FDA approved sustained release back of the eye treatments for chronic eye disease and has a next generation product in phase III clinical trials. pSivida also owns the right to develop and commercialize a new biomaterial, nanostructured porous silicon (BioSilicon™), for multiple potential applications in healthcare with a core focus on drug delivery. pSivida's strategic partner is QinetiQ (QQ.), the former United Kingdom Government Defence Evaluation & Research Agency (DERA) and Europe's largest research and development organization.